首页 > 市场调查报告书 > 製药

生物製剂

免疫疗法药物市场规模、份额和成长分析（按类型、应用、给药途径、分销管道、最终用户和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897536

免疫疗法药物市场规模、份额和成长分析（按类型、应用、给药途径、分销管道、最终用户和地区划分）－2026-2033年产业预测

Immunotherapy Drugs Market Size, Share, and Growth Analysis, By Type (Antibody Drugs Inhibitor Drugs, Interferons & Interleukins), By Application, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 174 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，免疫疗法药物市场规模将达到 3,289.5 亿美元，到 2025 年将达到 3,792.8 亿美元，到 2033 年将达到 11,846.6 亿美元，预测期（2026-2033 年）的复合年增长率为 15.3%。

受慢性疾病（包括糖尿病）日益增多的推动，免疫疗法市场正经历显着成长。这些疾病影响着全球数百万人口。该领域的企业正日益重视创新产品开发和策略合作，以加强其研发投入。疫情期间，人们对免疫疗法的关注度显着提升，导致其需求激增，凸显了单株抗体等治疗方法在治疗重症病例方面的有效性。监管机构正积极核准更多免疫疗法产品，进一步推动市场扩张。促成这一增长的关键因素包括：从传统疗法转向标靶治疗的转变、生物相似药的出现、与文明病相关的健康问题以及对单株抗体需求的激增。此外，生技和製药公司在研发倡议的合作与投入不断增加，也推动了市场的发展。

免疫疗法市场驱动因素

免疫疗法药物市场受到慢性疾病（包括癌症、自体免疫疾病和感染疾病）发病率上升的显着影响。随着人口老化和生活方式的改变，对有效治疗方法的需求持续增长。免疫疗法具有潜在的治癒潜力，进一步推动了其广泛应用和市场成长。此外，公众意识的提高和诊断能力的提升也促进了对这些创新治疗方法的需求激增。这些因素共同塑造了免疫疗法药物市场，并凸显了开发先进治疗方案以应对各种健康挑战的必要性。

免疫疗法市场限制因素

由于药物研发的复杂性和高成本，免疫疗法市场面临许多限制因素。临床试验、研究和开发所需的大量资金投入，为新型治疗方法进入市场设置了障碍。此外，免疫系统各组成部分之间的复杂相互作用，要求治疗方法必须针对每位患者或特定病患小组进行个别化定制。这些挑战共同阻碍了创新疗法的进步，并阻止了潜在的新进入者进入市场。因此，这些限制因素正在减缓整体市场成长和新型免疫疗法方案的进展。

免疫疗法药物市场趋势

在基因组学、精准医疗和基因工程的推动下，免疫疗法市场正经历着向个人化医疗的重大转变。这一新兴趋势着重于根据患者独特的基因组成、疾病史和免疫特征来客製化免疫疗法，从而提高疗效并最大限度地减少副作用。随着临床试验展现出个人化免疫疗法的良好前景，预计企业将加大投资，推动研发活动。这项变革有望彻底改变包括癌症和自体免疫在内的多种疾病的治疗方法，并推动免疫疗法领域的持续成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Merck & Co., Inc.（United States）
Johnson & Johnson Services, Inc.（United States）
F. Hoffmann-La Roche Ltd.（Switzerland）
AstraZeneca（United Kingdom）
Pfizer Inc.（United States）
Amgen Inc.（United States）
Novartis AG（Switzerland）
Eli Lilly and Company（United States）
Sanofi（France）
Bristol-Myers Squibb Company（United States）
Gilead Sciences, Inc.（United States）
Takeda Pharmaceutical Company Limited（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
AbbVie Inc.（United States）
GSK PLC（United Kingdom）
Immunocore Holdings Plc（United Kingdom）
Astellas Pharma Inc.（Japan）
Genmab A/S（Denmark）
MacroGenics, Inc.（United States）
Ferring BV（Switzerland）

简介目录

Product Code: SQMIG35I2354

Immunotherapy Drugs Market size was valued at USD 328.95 Billion in 2024 and is poised to grow from USD 379.28 Billion in 2025 to USD 1184.66 Billion by 2033, growing at a CAGR of 15.3% during the forecast period (2026-2033).

The immunotherapy drugs market is experiencing significant growth driven by the rising prevalence of chronic diseases, notably diabetes, affecting millions worldwide. Companies in this sector are increasingly focusing on innovative product development and strategic partnerships to enhance research efforts. The demand for immunotherapy escalated due to heightened attention during the pandemic, highlighting the efficacy of treatments like monoclonal antibodies in managing severe cases. Regulatory bodies are actively approving more immunotherapy products, further fueling market expansion. Key factors contributing to this growth include the shift towards targeted therapies over conventional treatments, the emergence of biosimilars, lifestyle-related health issues, and a surging demand for monoclonal antibodies. Additionally, heightened collaborations and investments in R&D initiatives by biotechnology and pharmaceutical firms are propelling market advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunotherapy Drugs Market Segments Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Immunotherapy Drugs Market

The immunotherapy drugs market is significantly influenced by the rising incidence of chronic illnesses, including cancer, autoimmune disorders, and infectious diseases. As populations age and lifestyle changes occur, the demand for effective treatment options continues to grow. Immunotherapies offer the promise of potential cures, which further fuels their adoption and market expansion. Moreover, heightened awareness and improved diagnostic capabilities are contributing to the surging demand for these innovative therapies. This combination of factors is essential in shaping the landscape of the immunotherapy pharmaceuticals market, emphasizing the need for advanced treatment solutions in response to widespread health challenges.

Restraints in the Immunotherapy Drugs Market

The immunotherapy drugs market faces significant constraints due to the challenging nature of drug development, which is both complex and costly. The substantial financial investments needed for clinical trials, research, and development create barriers to market entry for new therapies. Additionally, the intricate interactions among immune system components require therapies to be tailored specifically to individual patients or specific patient groups. These challenges collectively hinder the progression of innovative treatments and deter potential new entrants from participating in the market. Consequently, these limitations contribute to a slowdown in overall market growth and the advancement of novel immunotherapeutic options.

Market Trends of the Immunotherapy Drugs Market

The Immunotherapy Drugs market is experiencing a significant shift towards personalized medicine, propelled by advancements in genomics, precision medicine, and genetic engineering. This burgeoning trend focuses on tailoring immunotherapy treatments to individual patients based on their unique genetic compositions, disease histories, and immune profiles, resulting in enhanced therapeutic efficacy and minimized side effects. As clinical trials demonstrate the promising outcomes of personalized immunotherapies, increased investment from businesses is expected to bolster research and development initiatives. This evolution is poised to revolutionize treatment modalities for various conditions, including cancers and autoimmune disorders, thereby driving sustained growth within the immunotherapy sector.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Customer & Buying Criteria Analysis
Value Chain Analysis
Supply Chain Analysis
Pricing Analysis
Patent Analysis
Technology Analysis
Case Study Analysis
Regulatory Landscape

Immunotherapy Drugs Market, By Type

Market Overview
Antibody Drugs
Inhibitor Drugs
Interferons & Interleukins
Cancer Vaccines
Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

Market Overview
Intravenous Route of Administration
Subcutaneous Route of Administration
Other Routes of Administration

Immunotherapy Drugs Market, By Application

Market Overview
Cancer
Autoimmune & Inflammatory Diseases
Hematology
Osteology
Neurology
Other Applications

Immunotherapy Drugs Market, By Distribution Channel

Market Overview
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

Immunotherapy Drugs Market, By End User

Market Overview
Hospitals & Clinics
Ambulatory Surgical Centers
Others

Immunotherapy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunocore Holdings Plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genmab A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring BV (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments